Liu, Chen-Hua
Huang, Yi-Jie
Yang, Sien-Sing
Chang, Chung-Hsin
Yang, Sheng-Shun
Sun, Hsin-Yun
Liu, Chun-Jen
Liu, Wen-Chun
Su, Tung-Hung http://orcid.org/0000-0002-6747-7941
Yang, Hung-Chih
Hong, Chun-Ming
Tseng, Tai-Chung
Chen, Pei-Jer
Chen, Ding-Shinn
Hung, Chien-Ching
Kao, Jia-Horng http://orcid.org/0000-0002-2442-7952
Article History
Received: 12 June 2018
Accepted: 30 August 2018
First Online: 12 September 2018
Competing Interests
: Chen-Hua Liu: advisory board for Abbvie, Gilead Science, Merck Sharp & Dohme; speaker’s bureau for Abbott, Abbvie, Gilead Science, Merck Sharp & Dohme; research grant from Abbvie, Gilead Science, Merck Sharp & Dohme. Jia- Horng Kao: advisory board for Abbott, Abbvie, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Merck Sharp & Dohme, Novartis, Roche; speaker’s bureau for Abbott, Abbvie, Bayer, Bristol-Myers Squibb, Gilead Science, GlaxoSmithKline, Merck Sharp & Dohme, Novartis, Roche; Ding-Shinn Chen: advisory board for Abbvie, Gilead Science, GlaxoSmithKline, Merck Sharp & Dohme, Novartis; Pei-Jer Chen: advisory board for Abbvie, Novartis, Roche; Chien-Ching Hung: advisory boards for Abbvie, Gilead Sciences, Janssen, ViiV;. Speaker’s bureau for Abbvie, Bristol-Myers Squibb, Gilead Sciences, ViiV; research grant from Gilead Sciences, Janssen, Merck, ViiV. All other authors declare no competing interests.